Academic physician specialists’ views toward the unproven stem cell intervention industry: areas of common ground and divergence
- 1 April 2021
- journal article
- research article
- Published by Elsevier in Cytotherapy
- Vol. 23 (4) , 348-356
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Challenging Misinformation and Engaging Patients: Characterizing a Regenerative Medicine Consult ServiceRegenerative Medicine, 2020
- The Direct-to-Consumer Market for Stem Cell-Based Interventions in Australia: Exploring the Experiences of PatientsRegenerative Medicine, 2020
- Rapid Change of a Cohort of 570 Unproven Stem Cell Clinics in the USA Over 3 YearsRegenerative Medicine, 2019
- How to Peddle Hope: An Analysis of YouTube Patient Testimonials of Unproven Stem Cell TreatmentsStem Cell Reports, 2019
- Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based InterventionsStem Cells Translational Medicine, 2018
- Lancet Commission: Stem cells and regenerative medicineThe Lancet, 2018
- Can civil lawsuits stem the tide of direct-to-consumer marketing of unproven stem cell interventionsnpj Regenerative Medicine, 2018
- The US Direct-to-Consumer Marketplace for Autologous Stem Cell InterventionsPerspectives in Biology and Medicine, 2018
- Between hope and evidence: How community advisors demarcate the boundary between legitimate and illegitimate stem cell treatmentsHealth: An Interdisciplinary Journal for the Social Study of Health, Illness and Medicine, 2014
- A question of ethics: Selling autologous stem cell therapies flaunts professional standardsStem Cell Research, 2014